Chronic graft-versus-host disease (GVHD) remains a major late complication of allogeneic bone marrow transplantation (BMT). In a previous study, impaired thymic negative selection of the recipients permitted the emergence of pathogenic T cells that cause chronic GVHD using MHC class II-deficient (H2-Ab1 KO) B6 into C3H model and CD4 + T cells isolated from chronic GVHD mice caused chronic GVHD when administered into the secondary recipients. In this study, we evaluated the kinetics of regulatory T cell (Treg) reconstitution in wild type B6 into C3H model. After myeloablative conditioning, host Tregs 
Introduction
Chronic GVHD is the most serious late complication after allogeneic HSCT, but the pathophysiology and treatment strategy of chronic GVHD remain poorly defined (1) (2) (3) .
GVHD prophylaxis using calcineurin inhibitors, such as cyclosporine (CSA) and tacrolimus, reduces the expansion of effector T cells by blocking interleukin (IL)-2 and prevents acute GVHD, but fails to reduce chronic GVHD (4, 5) . Administration of CSA for up to 24 months, longer than the standard 6 months of CSA, also did not decrease the risk of chronic GVHD (6) . Several studies have indicated that the efficacy and safety of mammalian target of rapamycin (mTOR) inhibitor, rapamycin (RAPA), in refractory chronic GVHD patients (7) (8) (9) (10) . However, a recent randomized trial showed that the combination of RAPA and tacrolimus as GVHD prophylaxis failed to reduce chronic GVHD compared with tacrolimus and methotrexate (11) .
CD4
+ CD25 + Foxp3 + regulatory T cells (Tregs) have been shown to play an important role in the establishment of tolerance between recipient tissues and donor-derived immunity. A series of animal studies indicated that Tregs in the inoculum can prevent acute GVHD when injected together with donor T cells (12) (13) (14) . Based on the role of Tregs in the prevention of GVHD and on their dependence on IL-2, there is considerable concern regarding the impact of blocking IL-2 signaling or IL-2 production by the immunosuppressive agents used for prophylaxis of GVHD. Zeiser et al. reported that Tregs showed relative resistance to RAPA as a result of reduced usage of the mTOR pathway and functional PTEN, a negative regulator of the phosphatidyl-inositol 3-kinase (PI3K)/Akt/mTOR pathway in Tregs compared with conventional T cells (15) . In contrast to CSA, RAPA allowed expansion of adoptively transferred Treg cells and led to reduction of alloreactive T cell expansion when animals received Treg treatment in combination with RAPA. They also showed that a combination of RAPA plus IL-2 increased both expansion of donor natural Tregs and conversion of induced Tregs from donor conventional T cells, and suppressed acute GVHD (16) . These animal data suggest that RAPA and CSA have differential impacts on peripheral Tregs following BMT.
IL-2 signaling is pivotal for Treg homeostasis in the periphery and is also essential for naturally occurring Treg development in the thymus (17) (18) (19) . T cell repopulation following BMT is composed of two subsets: T cells derived from the donor splenic T cell inoculum and newly arising T cells from bone marrow (BM) inoculum. It has been shown that Tregs from the former pathway play an important role in acute GVHD, whereas, no previous study evaluated whether use of CSA for an extended period affects donor BM-derived Treg generation. We hypothesized that BM-derived Tregs comprise the long-term peripheral Treg pool and that CSA, but not mTOR inhibitors, causes impaired BM-derived Treg reconstitution, which has a negative impact on chronic GVHD. In the present study, we therefore evaluated effects of different immunosuppressants on two distinct Treg expansion reconstitution pathways and on the development of chronic GVHD. 
Materials and methods

Mice
Bone marrow transplantation (BMT)
Mice received transplants according to the standard protocol described previously (21, 22 
Assessment of GVHD
Following BMT, survival was monitored daily, and weight changes were assessed twice per week. The degree of clinically acute GVHD was assessed twice per week using a scoring system that sums changes in five clinical parameters: weight loss, posture, activity, fur texture, and skin integrity (maximum index, 10) as described previously (22) . Shaved skin from the interscapular region (approximately 2 cm 2 ), liver, and salivary gland specimens of recipients were fixed in 10% formalin, embedded in paraffin, sectioned, mounted on slides, and stained with hematoxylin and eosin. Skin slides were scored on the basis of dermal fibrosis, fat loss, inflammation, epidermal interface changes, and follicular drop-out (0 -2 for each category; the maximum score was 10) (21). Liver slides were scored based on bile duct injury and inflammation (0 -4 for each category), and the maximum score was 8 (25) .
Salivary gland slides were scored based on atrophy and inflammation (0 -3 for each category), and the maximum score was 6. All slides were scored by pathologists (T.K. and T.T.) blind to experimental group.
Immunohistochemistry
Immunohistochemical staining for Foxp3 and CD3 was performed using the high polymer (HISTOFINE simple stain, NICHIREI, Tokyo, Japan) method. Anti-Foxp3
(eBioscience) and anti-CD3 (Abcam, Cambridge, MA) were used to identify Tregs and effector T cells, respectively.
Flow cytometry
The mAbs used were unconjugated anti-CD16/32(2.4G2); FITC-, PE-, PerCP-, or 
Statistics
Data are given as means ± SEM. The survival curves were plotted using Kaplan-Meier estimates. Group comparisons of pathology scores were performed using the Mann-Whitney U test. Comparative analysis of cell ratios was performed by the unpaired two-tailed Student's t-test or Welch's t-test. In all analyses, P < 0.05 was taken to indicate statistical significance.
Results
Kinetics of Treg reconstitution after allogeneic bone marrow transplantation
We first examined whether Tregs intermixed in the graft persist in the host for long periods post-BMT using the major histocompatibility complex ( (Fig. 2D ). Taken together, Treg s generated from donor BM-derived progenitors comprise the long-term peripheral Treg pool and exhibit immunosuppressive activity.
CSA, but not mTORinhibitors, hampered reconstitution of BM-derived Treg
Coenen et al. reported that 28 days of CSA administration hampered Treg homeostasis in normal mice (28) . We examined whether use of CSA for an extended period affected the long-term peripheral Treg pool after BMT. C3H recipient mice were transplanted from B6 donor mice (as shown in Fig. 1 (Fig. 3A) . In the MLN, these three groups also showed similar Treg reconstitution kinetics (Fig. 3B ). There were no differences in the absolute numbers of Treg among the three groups on day 21. were observed in the salivary glands of CSA-treated mice (Fig. 5A ) and pathological scores were significantly higher in CSA-treated mice than in the controls ( Fig. 5C ; 4.0 ± 0.5 vs. 1.8 ± 0.1, P < 0.01). CSA-treated mice showed bile duct injury and fibrosis in the portal area and peripheral mononuclear cell infiltration in the liver and pathological scores of the liver also tended to be worse in CSA-treated mice, as compared to those treated with vehicle control, although it was not statistically significant ( Fig 5D) . In contrast to CSA, mice treated with RAPA showed no pathogenic features of chronic GVHD and there were no differences in pathogenic skin and salivary gland scores, as compared to control mice ( Although mouse models of chronic GVHD have provided important insights into pathophysiology of this disease, one factor that confounds the translation of findings in mouse models to the human disease is that time course of development of chronic GVHD is more rapid in most mouse models than in human. Another factor is that most patients are given immunosuppressive therapy to prevent acute GVHD (38) , and these medications might influence the development of chronic GVHD. In this study, histopathological examination revealed that CSA-treated mice showed pathogenic features of chronic GVHD, while those treated with mTOR inhibitors showed no significant differences compared with control mice.
This is the first report that long-term use of CSA induces chronic GVHD in transplant recipient mice. This may have been due to induction of autoreactive T cells by CSA(39, 40).
Wu et al. reported that CSA contributes to chronic GVHD in experimental models, which was ascribed to the disruption of clonal deletion mechanisms in the thymus, resulting in the export of autoreactive T cells (41) . The present study demonstrated another mechanism by which CSA impaired Treg reconstitution. Adoptive transfer of the pathogenic CD4 + T cells caused severe chronic GVHD in CSA-treated mice, while mTOR inhibitor-treated and control mice showed resistance to induction of chronic GVHD. These findings suggest that the increased liability to chronic GVHD in CSA treated mice might be due to limited reconstitution of BM-derived Treg cells; further mechanistic studies will be required to determine if this is truly causative rather than merely an association.
Here, we assessed the differential effects of CSA and mTOR inhibitors on the long-term Lethally irradiated C3H recipients were transplanted from B6 donor mice as shown in Fig. 1 and received i. Lethally irradiated C3H recipients were transplanted from B6 donor mice as shown in Fig. 1 and received CSA, RAPA, RAD, or vehicle control, daily from day 0 to 120. Data from two
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